RecruitingNot Applicable

A Large Language Model-based Chatbot for Alcohol Reduction in Patients With Metabolic Alcohol-Related Liver Disease

Hong Kong50 participantsStarted 2026-03-18

Plain-language summary

The goal of this pilot randomized controlled trial is to evaluate the trial feasibility and acceptability of LLM-based chatbot for reducing alcohol use among patients with metabolic alcohol-related liver disease. Specific objectives include: 1. To assess how many MetALD patients accept the invitation to participate in the trial 2. To assess the retention rate of the participants through 3 and 6 months after treatment initiation 3. To assess the acceptability of the LLM-based chatbot in terms of participants' compliance and usability rating 4. To estimate the intervention effect on alcohol reduction 5. To explore the participants' perception and experiences in the chatbot

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Evidence of hepatic steatosis (fat accumulation in the liver) confirmed by imaging techniques such as ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), or liver biopsy
✓. Presence of metabolic dysfunction, indicated by at least one of the following:

Exclusion criteria

✕. Diagnosed with mental disease or cognitive impairments, or
✕. Participating in other ongoing clinic trials

What they're measuring

Recruitment rate

Timeframe: Through recruitment completion, about 12 months

Retention rate

Timeframe: 6 months after randomisation

Weekly alcohol consumption

Timeframe: 3 months after randomisation

Trial details

NCT IDNCT07450144

SponsorThe University of Hong Kong

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-05-22

View on ClinicalTrials.gov More Metabolic Dysfunction-Associated Steatotic Liver Disease trials